BeOne Medicines Files 2026 Interim Report; Discloses PRC GAAP Financials

What Happened

• On August 26, 2026, BeOne Medicines Ltd. filed a Form 8-K to report that it submitted its 2026 Interim Report to the Shanghai Stock Exchange’s STAR Market for the six months ended June 30, 2026.
• The STAR Interim Report was prepared under China Accounting Standards for Business Enterprises (CAS) and other PRC accounting rules (collectively “PRC GAAP”) and includes additional PRC GAAP financial information for the Reporting Period.
• The Form 8-K attaches Exhibit 99.1, which furnishes the Company’s R&D expense allocations by key products and other R&D projects prepared in accordance with U.S. GAAP, plus a summary of material differences between PRC GAAP and U.S. GAAP.

Key Details

• Filing date: August 26, 2026; Reporting period: six months ended June 30, 2026.
• Financials in the STAR Interim Report are prepared under PRC GAAP (CAS); these differ from U.S. GAAP.
• Exhibit 99.1 (furnished with this 8-K) contains U.S. GAAP R&D expense allocations and a summary of material accounting differences.
• The STAR Interim Report is publicly available in Chinese on the Shanghai Stock Exchange website but is not incorporated by reference into the Company’s SEC filings.

Why It Matters

• Investors should note the company produced and filed interim financials under PRC GAAP, which can differ materially from U.S. GAAP; Exhibit 99.1 helps bridge those differences for R&D spending analysis.
• The R&D allocation information may affect how investors assess BeOne’s investment in product development and compare prior U.S. GAAP disclosures.
• The STAR report is available only in Chinese on the SSE site and is not treated as part of the Company’s SEC filing, so U.S. investors should rely on the Exhibits filed with the 8-K (not the Shanghai listing pages) for information incorporated into SEC records.